Which federal agency does National Community Pharmacists Association comment on most?

National Community Pharmacists Association is most active at the Food and Drug Administration.

National Community Pharmacists Association

Unclaimed

Website

Engagement overview

National Community Pharmacists Association has filed 165 public comments across 137 dockets at 8 federal agencies, most actively at the Food and Drug Administration.

National Community Pharmacists Association

Engagement overview

Is this your organization?

Agency footprint

Dockets · FDA (91)

Agency Information Collection Activities; Proposed Collection; Comment Request; Medication Guides for Prescription Drug Products

Food and Drug Administration Expert Panel on Testosterone Replacement Therapy for Men; Request for Information

Increasing Availability of Nonprescription Drugs; Request for Information

Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act

Agency Information Collection Activities; Proposed Collection; Comment Request; Proposed Small Dispensers Assessment under the Drug Supply Chain Security Act

FDA Expert Panel on Menopause and Hormone Replacement Therapy for Women

Agency Information Collection Activities; Proposed Collection; Comment Request; Compounding Animal Drugs from Bulk Drug Substances

Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments--Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List

Listening Session: Optimizing FDA’s Use of and Processes for Advisory Committees; Public Meeting; Request for Comments

Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act

Compounding of Human Drug Products Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket

Medication Guides: Patient Medication Information; Proposed Rule

Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket; Request for Information and Comments

Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act

Development of Small Dispensers Assessment under the Drug Supply Chain Security Act; Request for Comments

In-Home Safe Disposal Systems; Request for Information

Prohibition on Wholesaling Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry; Availability

Safety and effectiveness of certain naloxone hydrochloride drug products for nonprescription use; Request for Comments

Nonprescription Drug Product With an Additional Condition for Nonprescription Use; Proposed Rule

Revising the National Drug Code Format and Drug Label Barcode Requirements

Proposal to Withdraw Marketing Approval; Notice of Opportunity for a Hearing

Identifying Trading Partners Under the Drug Supply Chain Security Act

DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs: How to Exchange Product Tracing Information; Availability

Providing Mail-Back Envelopes and Education on Safe Disposal With Opioid Analgesics Dispensed in an Outpatient Setting; Establishment of a Public Docket; Request for Comments

Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

Medical Devices; Ear, Nose, and Throat Devices; Establishing Over-the-Counter Hearing Aids and Aligning Other Regulations

Hospital and Health System Compounding Under the Federal Food, Drug, and Cosmetic Act

Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

Fixed-Quantity Unit-of-Use Blister Packaging for Certain Immediate-Release Opioid Analgesics for Treatment of Acute Pain; Establishment of a Public Docket; Request for Comments

Compounding Animal Drugs from Bulk Drug Substances; Draft Guidance for Industry; Availability

Importation of Prescription Drugs

Importation of Certain FDA-Approved Human Prescription Drugs, Including Biological Products, under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry; Availability

Amendments to the List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act

Compliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients With Tetrahydrobiopterin (BH4) Deficiency; Immediately in Effect Guidance for Industry; Availability

Memorandum of Understanding Addressing Certain Distributions of Compounded Drug Products Between the States and the Food and Drug Administration; Revised Draft; Availability

Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing; Request for Comments

Nonproprietary Naming of Biological Products

Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs; Draft Guidance for Industry; Availability

Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions; Public Meeting; Request for Comments

Future Format of the National Drug Code; Public Hearing; Request for Comments

Insanitary Conditions at Compounding Facilities

Innovative Approaches for Nonprescription Drug Products; Draft Guidance for Industry; Availability

Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act

Opioid Policy Steering Committee prescribing intervention – exploring a strategy for implementation; Public Hearing; Request for Comments

Review of Existing Center for Drug Evaluation and Research Regulatory and Information Collection Requirements

Opioid Policy Steering Committee

Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications

Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

Administering the Hatch-Waxman Amendments: Ensuring an Appropriate Balance Between Innovation and Access

Training for Opioid Analgesic Prescribers--Exploring the Path Forward

List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act

Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers: Questions and Answers; Draft Guidance for Industry; Availability

Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry; Availability

Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act

Patient and Medical Professional Perspectives on the Return of Genetic Test Results

The Drug Supply Chain Security Act Implementation: Product Tracing Requirements for Dispensers - Compliance Policy

Compounding Animal Drugs from Bulk Drug Substances

Designation of Official Names and Proper Names for Certain Biological Products

Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products Between the States and the Food and Drug Administration

Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities

Bulk Drug Substances That May Be Used to Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act; Request for Nominations

Standards for the Interoperable Exchange of Information for Tracing of Human, Finished, Prescription Drugs, in Paper or Electronic Format; Request for Comments

Standardizing and Evaluating Risk Evaluation and Mitigation Strategies

Pharmacy Compounding of Human Drug Products under Section 503A of the Federal Food, Drug, and Cosmetic Act

Food and Drug Administration Drug Shortages Task Force and Strategic Plan; Request for Comments

Drug Safety and Risk Management Advisory Committee; Notice of Meeting

Framework for Pharmacy Compounding: State and Federal Roles

Draft Guidance for Industry on Notification to FDA of Issues that May Result in a Prescription Drug or Biological Product Shortage

Using Innovative Technologies and Other Conditions of Safe Use To Expand Which Drug Products Can Be Considered Nonprescription

Prescription Drug Product Labeling: Medication Guide Requirements

Center for Drug Evaluation and Research, Approach to Addressing Drug Shortage; Public Workshop, Request for Comments

Draft Blueprint for Prescriber Education for Long-Acting/Extended-Release Opioid Class-Wide Risk Evaluation and Mitigation Strategy; Availability; Request for Comments

Determination of System Attributes for the Tracking and Tracing of Prescription Drugs; Public Workshop